ArticleScience advances2026
Sequential clearance of neutrophil extracellular traps for precision therapy of sepsis.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis, a life-threatening syndrome driven by dysregulated host response to infection, is critically exacerbated by the uncontrolled formation of neutrophil extracellular traps (NETs), which amplify inflammation, promote microthrombosis, and precipitate multiple organ dysfunction. However, current therapeutic approaches remain inadequate in effectively targeting and modulating NETs, leaving a significant clinical gap in managing sepsis progression. Herein, we propose a "sequential NETs-clearance" strategy to precisely mitigate NET-associated pathologies by simultaneously inhibiting NET overproduction and facilitating their targeted capture and degradation. We engineered a multifunctional metal-organic framework (MOF818) with intrinsic antioxidant activity, functionalized with a NETs-capturing poly(amidoamine) dendrimer and loaded with a NETs-degrading enzyme, micrococcal nuclease (MNase). This integrated platform efficiently scavenges excessive reactive oxygen species (ROS) to inhibit NETosis, while simultaneously capturing existing NETs via electrostatic interactions and enzymatically cleaving their DNA scaffold, thereby disrupting the self-sustaining inflammatory cascade. In vitro, this combinatorial treatment markedly reduced NET-mediated inflammatory responses, while treatment in murine models of sepsis significantly mitigated systemic cytokine storms, alleviated organ damage, and improved survival in septic mice. Importantly, this therapeutic efficacy was corroborated in ex vivo human specimens, where the nanocomposite significantly suppressed NETosis and reduced inflammatory cytokines in neutrophils and plasma derived from sepsis patients. This work establishes a versatile nanotherapeutic paradigm for multi-target modulation of NETs and oxidative stress, offering a promising translational avenue for the precise treatment of sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.